Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. briscrew

BriScrew

BioResorbable Ostheosynthesis Implant

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BriScrew project word cloud

Explore the words cloud of the BriScrew project. It provides you a very rough idea of what is the project "BriScrew" about.

13    engineering    stress    merely    composition    surgery    2020    aluminium    orthopaedic    organism    implant    earn    81    revolutionary    team    natural    total    disease    payback    zirconium    alloyed    global    risk    sell    osteosynthesis    earth    operation    introduce    treatment    investment    95    2m    consists    zn    off    hire    magnesium    healing    gold    purified    market    conventional    launch    5    bone    individuals    secondary    minimize    almost    bioresorbable    pain    hospital    feeling    commercialization    7m    too    mg    materials    steel    remove    healthcare    patient    foresee    pay    injuries    900    quality    reduces    titanium    silver    employees    sales    stimulates    profit    standard    alloy    risks    screw    adverse    commercializing    prevent    fractures    medicine    performed    biodegradable    extremely    qualified    time    removal    temperature    shielding    unpredictable    q3    bri    frequently    stiff    assurance    rare    implants    infections    metal    roi    ca    screws    surgical    generate   

Project "BriScrew" data sheet

The following table provides information about the project.

Coordinator		 BRI.TECH GMBH 

Organization address
address: ROSSMANNGASSE 21/4
city: GRAZ
postcode: 8010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Austria [AT]
 Project website http://britech.eu/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRI.TECH GMBH AT (GRAZ) coordinator 50˙000.00

Map

 Project objective

In the EU, 20 % of all hospital treated injuries are bone fractures. If surgical treatment of bone fractures is necessary, it is currently performed with standard metal implants. Conventional gold-standard titanium or steel implants are too stiff, have adverse effects on the patient (feeling of pain during temperature changes) and lead to stress-shielding. Their usage is associated to the risk of infections and bone loss. Often a secondary surgery for removal is needed which is associated with almost 50 % higher healthcare costs. When Mg-based implants are used they are frequently alloyed with rare earth elements, aluminium, silver or zirconium. However, zirconium reduces the healing properties, aluminium and rare earth elements may remain in the organism and can lead to unpredictable effects, while the application of silver might result in a silver-disease.

Within the BRI.SCREW project we will introduce to the market revolutionary osteosynthesis implants that do not need surgical removal. We will use our own bioresorbable magnesium alloy which consists merely out of extremely high purified natural materials including Mg, Ca and Zn. BRI.SCREW is 100 % biodegradable, stimulates the healing process of the bone and has no side effects due to the implant's composition. Our orthopaedic implants will prevent the need of a second operation to remove the implant and will therefore minimize patient costs and surgical risks.

Our team consists of highly qualified individuals with experience in medicine, engineering and quality assurance. The investment in BRI.SCREW will pay off. We have estimated that after 5 years from launch, we will sell in total 81.900 BRI.SCREWs (sales €13.2M), hire 10 technical employees, and manage 5% of the global market. We will earn €8.7M profit and generate a ROI of 3.95 by commercializing this technology. We foresee the payback time in 2 years after commercialization (in Q3 of 2020).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRISCREW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRISCREW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More